Huabin Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huabin Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adriana L. Gramer
Department of Pathology Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Amanda Barrett
Department of Pathology Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication Brian Montoya
Research and Development Department, Advanced RNA Vaccine Technologies, Inc., North Bethesda, MD, United States
1 shared publicationCarolina R. Melo-Silva
Research and Development Department, Advanced RNA Vaccine Technologies, Inc., North Bethesda, MD, United States
1 shared publication- Chandramukhi S. Panda
Departments of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Daley S. Morera
Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication
Latest Publications
- Open Access
Novel Molecular Signatures Selectively Predict Clinical Outcomes in Colon Cancer
Among the 152,810 estimated new cases of adenocarcinoma of the colon (COAD) and the rectum (READ) in 2024, the rates of colorectal cancer (CRC) are increasing in young adults (age < 55 years)
Open AccessNovel Molecular Signatures Selectively Predict Clinical Outcomes in Colon Cancer
Among the 152,810 estimated new cases of adenocarcinoma of the colon (COAD) and the rectum (READ) in 2024, the rates of colorectal cancer (CRC) are increasing in young adults (age < 55 years)
- Open Access
- 23 March 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1126392
Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
Because of the rapid mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an effective vaccine against SARS-CoV-2 variants is needed to prevent coronavirus disease 2019 (COVID-19). T cells, in addition to neutralizing antibodies, are an important component of naturally acquired protective immunity, and a number of studies have shown that T cells induced by natural infection or vaccination contribute significantly to protection against several viral infections including SARS-CoV-2. However, it has never been tested whether a T cell-inducing vaccine can provide significant protection against SARS-CoV-2 infection in the absence of preexisting antibodies. In this study, we designed and evaluated lipid nanoparticle (LNP) formulated mRNA vaccines that induce only T cell responses or both T cell and neutralizing antibody responses by using two mRNAs. One mRNA encodes SARS-CoV-2 Omicron Spike protein in prefusion conformation for induction of neutralizing antibodies. The other mRNA encodes over one hundred T cell epitopes (multi-T cell epitope or MTE) derived from non-Spike but conserved regions of the SARS-CoV-2. We show immunization with MTE mRNA alone protected mice from lethal challenge with the SARS-CoV-2 Delta variant or a mouse-adapted virus MA30. Immunization with both mRNAs induced the best protection with the lowest viral titer in the lung. These results demonstrate that induction of T cell responses, in the absence of preexisting antibodies, is sufficient to confer protection against severe disease, and that a vaccine containing mRNAs encoding both the Spike and MTE could be further developed as a universal SARS-CoV-2 vaccine.
- 23 March 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1126392
Open AccessDesign and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine
Because of the rapid mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an effective vaccine against SARS-CoV-2 variants is needed to prevent coronavirus disease 2019 (COVID-19). T cells, in addition to neutralizing antibodies, are an important component of naturally acquired protective immunity, and a number of studies have shown that T cells induced by natural infection or vaccination contribute significantly to protection against several viral infections including SARS-CoV-2. However, it has never been tested whether a T cell-inducing vaccine can provide significant protection against SARS-CoV-2 infection in the absence of preexisting antibodies. In this study, we designed and evaluated lipid nanoparticle (LNP) formulated mRNA vaccines that induce only T cell responses or both T cell and neutralizing antibody responses by using two mRNAs. One mRNA encodes SARS-CoV-2 Omicron Spike protein in prefusion conformation for induction of neutralizing antibodies. The other mRNA encodes over one hundred T cell epitopes (multi-T cell epitope or MTE) derived from non-Spike but conserved regions of the SARS-CoV-2. We show immunization with MTE mRNA alone protected mice from lethal challenge with the SARS-CoV-2 Delta variant or a mouse-adapted virus MA30. Immunization with both mRNAs induced the best protection with the lowest viral titer in the lung. These results demonstrate that induction of T cell responses, in the absence of preexisting antibodies, is sufficient to confer protection against severe disease, and that a vaccine containing mRNAs encoding both the Spike and MTE could be further developed as a universal SARS-CoV-2 vaccine.